Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

about

Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors

P2860

Q36009618-8C6A645F-2E9C-4222-A258-2C8F3B771D20

P2860

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

Item

http://www.wikidata.org/entity/Q42807577

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

@en

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

@nl

type

Item

label

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

@en

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

@nl

prefLabel

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

@en

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

@nl

P1476

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

@en

P2093

Francis J Giles

http://www.w3.org/2001/XMLSchema#string

Kamalesh Sankhala

http://www.w3.org/2001/XMLSchema#string

P2860

The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Reassessment of the role of FKBP38 in the Rheb/mTORC1 pathway

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

P304

399-414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/EHM.09.31

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21082945

http://www.w3.org/2001/XMLSchema#string

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

about

P2860

P2860

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698